5KC.F PILA PHARMA AB
- Market cap
- EUR 5.98M
- P/E
- -
- P/B
- 4.15x
- ROE
- -116.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 5KC.F undervalued?
Graham numberThe Graham number of PILA PHARMA AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PILA PHARMA AB fundamental analysis
No fundamental analysis for PILA PHARMA AB yet.
PILA PHARMA AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PILA PHARMA AB
Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.
Full company profilePILA PHARMA AB financial statements
PILA PHARMA AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 1.88M | 1.46M | 775K | 1.13M |
| Gross Profit | 1.88M | 1.46M | - | - |
| Operating Income | -8.89M | -6.39M | -8.11M | -8.03M |
| EBITDA | -26.8M | -8.81M | -10.2M | -15.9M |
| Net Income | -26.8M | -9.93M | -11.2M | -17.0M |
| EPS | -1.30 | -0.37 | -0.37 | -0.40 |
| Balance Sheet | ||||
| Total Assets | 10.9M | 8.46M | 6.22M | 16.2M |
| Total Liabilities | 1.36M | 1.79M | 962K | 1.57M |
| Shareholders' Equity | 9.53M | 6.66M | 5.26M | 14.6M |
| Cash & Short-term Investments | 7.24M | 5.95M | 4.89M | 15.9M |
| Cash Flow | ||||
| Operating Cash Flow | -9.09M | -4.85M | -7.82M | -6.63M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -9.09M | -4.85M | -7.82M | -6.63M |
| Ratios | ||||
| ROE | -281.0% | -149.1% | -213.7% | -116.1% |
| ROA | -246.0% | -117.4% | -180.6% | -104.8% |
| Net Profit Margin | -1,423.7% | -678.7% | -1,450.7% | -1,509.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PILA PHARMA AB dividends
PILA PHARMA AB has not paid dividends in the last 5 fiscal years.
Who owns PILA PHARMA AB
- Insiders 34.56%
- Institutions 3.12%
- Public & others 62.32%
- Shares outstanding 45.7M
- Free float 30.4M
PILA PHARMA AB company profile
- Company name
- PILA PHARMA AB
- Ticker
- 5KC.F
- ISIN
- SE0015988274
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- Norra Vallgatan 72, Malmö, Sweden, 211 22
- Phone
- 46 7 39 03 69 69
- Website
- pilapharma.com
About PILA PHARMA AB
Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.
PILA PHARMA AB management
10- Ms. Dorte Xenia GramFounder, Chairman & Chief Scientific Officer · born 1969
- Mr. Gustav Hanghoj GramChief Executive Officer · born 1993
- Mr. Hampus DarrellChief Financial Officer · born 1973
- Mr. Miguel LecumberriHead of Compliance & Legal Affairs
- Mr. Masoud AlaviHead of Corporate Visual Communication
- Mr. Andy MakinHead of Toxicology
- Ms. Maura McArdleHead of BD & Quay Pharma
- Mr. Mike FrodshamCTO of Quay Pharma
- Ms. Alison FosterHead of Pre-Clinical - Quay Pharma
- Mr. Simon HamiltonHead of Global Business Development - Almac